$1.92
0.75% today
Nasdaq, Feb 28, 04:19 pm CET
ISIN
US45254U1016
Symbol
IMRN
Sector
Industry

Immuron Limited Sponsored ADR Stock price

$1.91
-0.04 2.05% 1M
-0.74 27.92% 6M
+0.21 12.35% YTD
+0.09 4.77% 1Y
-0.99 34.14% 3Y
-2.59 57.56% 5Y
+1.77 1,260.40% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.05 2.30%
ISIN
US45254U1016
Symbol
IMRN
Sector
Industry

Key metrics

Market capitalization $11.15m
Enterprise Value $3.48m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.08
P/S ratio (TTM) P/S ratio 3.47
P/B ratio (TTM) P/B ratio 1.28
Revenue growth (TTM) Revenue growth 164.30%
Revenue (TTM) Revenue $3.21m
EBIT (operating result TTM) EBIT $-5.65m
Free Cash Flow (TTM) Free Cash Flow $-3.66m
EPS (TTM) EPS $-0.80
P/E forward negative
P/S forward 3.26
EV/Sales forward 1.17
Short interest 0.54%
Show more

Is Immuron Limited Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Immuron Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Immuron Limited Sponsored ADR:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Immuron Limited Sponsored ADR:

Buy
100%

Financial data from Immuron Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
3.21 3.21
163% 163%
100%
- Direct Costs 1.03 1.03
212% 212%
32%
2.19 2.19
149% 149%
68%
- Selling and Administrative Expenses 4.32 4.32
36% 36%
135%
- Research and Development Expense 3.52 3.52
102% 102%
110%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5.65 -5.65
40% 40%
-176%
Net Profit -4.55 -4.55
78% 78%
-142%

In millions USD.

Don't miss a Thing! We will send you all news about Immuron Limited Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immuron Limited Sponsored ADR Stock News

Neutral
GlobeNewsWire
about one month ago
Sales Highlights: Global December 2024 Quarter AUD$2.5 million up 70% on prior quarter, up 249% on pcp December 2024 Half Year AUD$4.0 million up 70% on pcp Australia December 2024 Quarter AUD$1.9 million up 83% on prior quarter, up 314% on pcp December 2024 Half Year AUD$2.9 million up 54% on pcp North America December 2024 Quarter AUD$0.7 million up 43% on prior quarter, up 141% on pcp Decemb...
Neutral
GlobeNewsWire
about one month ago
Highlights: New Research Collaboration w ith Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum therapeutic drug products Second project proposal will focus on the Develop of new therapeutic drug candidates against Vancomycin-resistant enterococci (VRE) MELBOURNE, Australia, Jan. 15, 2025 (GLOBE NEWSWIRE) --  Immuron Limited (ASX: IMC; NASDAQ: ...
Neutral
GlobeNewsWire
about 2 months ago
Highlights: Travelan® (IMM-124E) Phase 2 Clinical Study Report submitted to the FDA Travelan® (IMM-124E) Phase 2 Clinical Study Statistically Significant Immunology Results Travelan® (IMM-124E) Phase 2 Clinical Study Statistically Significant Microbiome Responses Travelan® P2TD (n=866) Uniformed Services University field study randomized 776 subjects MELBOURNE, Australia, Jan. 14, 2025 (GLOBE N...
More Immuron Limited Sponsored ADR News

Company Profile

Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. It operates through the following segments: Research and Development, and HyperImmune Products.The Research and Development segment involves the R&D projects performed in Australia, Israel, and United States. The HyperImmune Products segment comprises of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.

Head office Australia
CEO Steven Lydeamore
Founded 1994
Website www.immuron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today